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 20 
Abstract 21 
Background: To examine the effect of acute R.Rosea ingestion, acute caffeine ingestion or 22 
combined caffeine and R.Rosea on 5km running time trial performance. 23 
Methods: Twelve male, recreational exercisers (mean age ± S.D. = 24.6 ± 6 years) undertook 24 
4 trials each (Placebo; Caffeine (3 mg/kg
-1
), R.Rosea (3 mg/kg
-1
), Caffeine (3 mg/kg
-1
) and 25 
R.Rosea (3 mg/kg
-1
)) in a double blind, randomised order. 26 
 Results: There was a small but significant main effect of treatment for 5km run time (P = 27 
.048) where performance was faster in the presence of caffeine compared to placebo but not 28 
between any other combination of trials. Heart Rate, Blood Lactate and RPE all increased 29 
with Km run, irrespective of substance ingested (all P<.05). Scores for Felt Arousal increased 30 
pre ingestion to post ingestion (P = .028) and were maintained to post exercise (P = .026) 31 
irrespective of substance ingested. There was a small, significant treatment X time interaction 32 
(P = .011, Pɳ2 =.255) for Feeling Scale scores, where post exercise feeling scale scores were 33 
significantly lower after caffeine ingestion compared to the other substances ingested. 34 
Conclusions: Acute caffeine ingestion (3 mg·kg
-1
) enhances 5km time trial performance 35 
undertaken on a treadmill and results in more negative affect post exercise as compared to 36 
ingestion of R.Rosea, combined R.Rosea and caffeine and placebo This study supports the 37 
efficacy of caffeine, but not R.Rosea, as an ergogenic aid for time running performance. 38 
Keywords: Ergogenic; supplementation; feeling states; affect 39 
  40 
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 41 
Introduction  42 
The performance enhancing effects of caffeine ingestion on endurance
1
 and short term, high 43 
intensity performance
2
 are well documented. However, less data is available that considers 44 
the effect of caffeine on shorter term endurance type activities (typically lasting <30min).
3
 45 
Bridge and Jones
4
 reported that caffeine ingestion enhanced 8km run time by 1.3% and more 46 
recent research by O’Rourke et al,3 reported that 5 mg/kg-1 caffeine resulted in small but 47 
significant improvements (1%) in 5km time trial performance in recreational and well-trained 48 
runners. This appears to be the only study that has examined the efficacy of caffeine ingestion 49 
on 5km running time, a commonly used race distance for trained and recreational runners 50 
alike. Thus, additional research may be warranted using this distance specifically. 51 
 There have also been recent calls to examine the efficacy of caffeine ingestion 52 
alongside ingestion of other supplements,
5
 based on the rationale that many athletes consume 53 
multiple substances in the belief they are both ergogenic and synergistic without substantial 54 
scientific evidence for this assumption. This is an important point as although two given 55 
substances might theoretically act synergistically, when combined there may be practical 56 
considerations which confound a substance’s positive effect. It is thus important to 57 
experimentally examine combination of substances to best direct applied nutritional guidance 58 
for athletes. Once such substance, Rhodiola Rosea (R.Rosea), has been cited as having a 59 
number of ergogenic benefits related to exercise
6,7
 and may be synergistic with caffeine due 60 
to its recently purported effect as a natural opioid
6
. Recent studies have identified antioxidant 61 
and anti-inflammatory properties of R.Rosea,
8,9
 and further work has suggested ingestion of 62 
R.Rosea appears to be effective, either acutely
10,11
 or with daily supplementation,
11
 for 63 
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reducing perceived fatigue, improving cognition,
9,12
 as well as reducing markers of 64 
physiological and psychological stress.
13
 65 
The efficacy of R.Rosea ingestion during exercise is unclear. Animal based research 66 
has shown increased swim time to exhaustion in rats.
8,14
 In humans, some studies have shown 67 
no effect of R.Rosea ingestion on exercise performance
9,15
 whilst others have supported its 68 
use.
17,18
 For example, research by Noreen et al
18
 reported that a 3 mg·kg
-1
 body mass dose of 69 
R.Rosea significantly decreased exercise heart rate, RPE and improved 6-mile time trial 70 
performance time. Subsequent work has reported that acute R.Rosea ingestion resulted in 71 
lower ratings of perceived exertion and increased mood state ratings during 30mins cycling at 72 
70% OV 2 max.
11
 Studies have suggested that R.Rosea acts to acutely increase endogenous 73 
opioid production or receptor sensitivity
7,17
 subsequently impacting on brain dopamine and 74 
and attenuating perception of effort at a given workload.
18
 However, as few studies have 75 
examined acute R.Rosea ingestion on exercise performance to date further data is needed on 76 
this topic.  77 
As caffeine is a known ergogenic which has direct effects of muscle and the CNS and 78 
R.Rosea acts as an opioid, promoting more positive exercise based affective responses, it may 79 
be possible that when these substances are combined performance gains are augmented due 80 
to the mechanism by which both substances are purported to work. This study aims to build 81 
on the recommendations of Burke
5
 by examining the effect of acute R.Rosea ingestion, acute 82 
caffeine ingestion or combined caffeine and R.Rosea on 5km running time trial performance 83 
in a population of recreationally-active men.   84 
 85 
Method 86 
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Subjects 87 
Following institutional ethics approval and informed consent, 12 male, recreational exercisers 88 
(mean age ± S.D. = 24.6 ± 6 years), recruited from University fitness classes/running groups, 89 
participated in this study. Inclusion criteria included being male and habitually engaged in 90 
recreational physical activity of more than 3 but less than 10 hours per week and not 91 
including formal competitive sports performance.  92 
Design  93 
This study employed a randomised within-participants double-blind cross-over design 94 
whereby participants visited the laboratory on 5 occasions in a well-rested and well hydrated 95 
state (one familiarisation trial, four experimental trials). All participants completed a health 96 
screen questionnaire prior to participation. All trials occurred in the morning for all 97 
participants and, for each participant, the 5 trials occurred at the same time of day with each 98 
participant completing all trials.  99 
 100 
Methodology 101 
All participants were asked to refrain from vigorous exercise and maintain normal 102 
dietary patterns in the 48 hours prior to testing and were asked to abstain from caffeine 24 103 
hours before testing. Habitual caffeine intake was 119.3 ± 21.1 mg day. During the first visit 104 
participants completed a familiarization session. Here participants the exercise affect 105 
measures to be used in the subsequent experimental trials were presented and explained. In 106 
addition the participants also completed an incremental exercise test to assess VO2max. The 107 
incremental exercise test was treadmill based (Woodway, Wisconsin, USA) and performed 108 
using the Jones
19
 protocol for determination of maximal oxygen uptake. Expired gas was 109 
collected via an online breath by breath system (Metamax 3B, Cortex Biophysik, Leipzig, 110 
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Germany) with recording of VO2 consumed, VCO2 produced, respiratory exchange ration nd 111 
ventilation rate and volume. Heart rate (Polar Electro, Kempele, Finland) and rating of 112 
perceived exertion (RPE), using the Borg 6-20 RPE scale,
20
 was recorded during the final 15 113 
seconds of each workload. Recognised criteria for the attainment of OV 2max was employed.
21
 114 
Mean ± S.D. of participants’ baseline OV 2 max values was 56.1 ± 7.1 ml·kg
-1
·min
-1
.  115 
 116 
Experimental protocol 117 
On completion of the OV 2max testing and following a period of at least 72 hours 118 
participants completed four, 5-km running time trials in a fasted state. During each trial 119 
participants were instructed to complete 5-km in the fastest time possible. Trials were 120 
conducted on a Woodway Treadmill (Woodway, Wisconsin USA) with gradient set at 1% 121 
and with participants having access to speed controls. All other controls (eg gradient) and 122 
visual display information (eg running speed, time) was blinded from participants using a 123 
purpose built shield to prevent pacing during the trials.  124 
Self-report of dietary intake was employed to assess dietary intake in the 24 hours 125 
prior to exercise trials. Participants were requested to maintain the same diet prior to each 126 
exercise trial in relation to general content of carbohydrate, fat and protein. They were also 127 
asked to refrain from consumption of caffeine and alcohol the day before each trial. 128 
Participants also verbally confirmed this was the case prior to each trial. This was used to 129 
ensure that caffeine and alcohol had not been consumed in the 24 hours prior to testing. 130 
Conditions were randomised, separated by 48-72 hours, and consisted of a R.Rosea condition 131 
where 3 mg·kg
-1
 body mass of R.Rosea (3% rosavins and 1% salidrosides, Indigo Herbs, 132 
Glastonbury, UK) was ingested, A caffeine condition where 3 mg·kg
-1
 body mass of caffeine 133 
(Myprotein, Cheshire, UK) was ingested, a combined R.Rosea and caffeine condition where 134 
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3 mg·kg
-1 
body mass of both substances was ingested  and a placebo (3 mg·kg
-1
 body mass of 135 
maltodextrin, (MyProtein, Northwich, UK)) was ingested. Experimental solutions were 136 
administered double-blind. In addition to the relevant solute, each solution consisted of 4 137 
ml.kg
-1
 tap water and 1 ml.kg
-1
 of double strength no added sugar orange squash 138 
(Sainsbury’s, London, UK). The amount of total maltodextrin ingested was approximately 139 
170 mg in the placebo condition and thus highly unlikely to have had any impact on exercise 140 
performance or metabolism.
18
 The dose of R.Rosea used was based on the previous work 141 
using this substance.
11,17,18
 142 
During each time trial, heart rate (monitored via Polar RS400, Polar Electro Oy, 143 
Kempele, Finland),blood lactate concentration (BLA: mmol/l) taken from a fingertip 144 
capillary blood sample (5 µl, Lactate Pro, Arkray Inc, Japan), and ratings of perceived 145 
exertion (RPE) using the Borg 6-20 scale
20
 were recorded after every 1 kilometre. The 146 
memory-anchoring approach
22
 was employed to anchor RPE scores before the experimental 147 
trials. Prior to substance ingestion, 60 min after ingestion (at the onset of each exercise bout) 148 
and immediately on completion of each exercise bout, participants completed the feeling 149 
scale (FS).
23
 This 11 item, single item scale ranges from +5 (very good) to -5 (very bad) and 150 
is used to quantify pleasure/displeasure. The Felt Arousal Scale (FAS) was also employed as 151 
a measure of state arousal.
24
 This is a six item scale ranges from 1 (low arousal) to 6 (high 152 
arousal). Participants were introduced to these scales on first visit to the laboratory (prior to 153 
establishment of OV 2max). Standardised instructions for completing the FS and FAS were 154 
read to participants at the beginning of each trial. 155 
 156 
Statistical Analysis 157 
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Data were analysed in a number of ways. A repeated measures analysis of variance 158 
(ANOVA) with substance ingested as the within subjects factor was used to examine any 159 
differences in total 5km time between conditions. In order to examine any within trial 160 
variation a 4 (substance ingested) X 5 (time per km) ways repeated measures ANOVA was 161 
used to examine any differences in running time per kilometre between the four conditions. A 162 
series of 4(substance ingested) X 5 (time point) ways repeated measures ANOVAs were used 163 
to examine any changes in heart rate, BLa and RPE at each kilometre of the time trial. A 164 
series of 4 (substance ingested) X 3 (time point, pre ingestion, post ingestion but pre exercise 165 
and post exercise) ways repeated measures analysis of variance was used to examine any 166 
differences in perceptions of arousal and pleasure/displeasure. Where any significant 167 
differences were discovered Bonferroni pairwise multiple comparisons were used to 168 
determine where the differences lay. Partial η2 was used as a measure of effect size, statistical 169 
significance was set at P = .05 a priori, and the Statistical Package for Social Sciences 170 
(Version 22) was used for all analysis (SPSS inc, Illinois, USA). 171 
 172 
Results 173 
There was a small but significant main effect of treatment for 5km run time (F 3,33 = 2.935, 174 
P = .048, Pɳ2 = .211; Table 1). Post-Hoc analysis indicated significant differences between 175 
placebo conditions and caffeine conditions (Mean diff = 78.6, P = .024) but not between any 176 
other combination of trials (all P>.05). There was a trend (P = .06) for 5km run to be faster in 177 
the caffeine condition compared to the R.Rosea condition. Mean ± SE of 5km time trial 178 
across treatment conditions is presented in Figure 1. 179 
 180 
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***Table 1 Here*** 181 
 182 
 183 
When data were considered using individual time per kilometre and across treatment 184 
conditions, the small main effect for total time remained (P = .048, Pɳ2 = .211) and there was 185 
a moderate significant main effect for time per kilometre (P = .001, Pɳ2 = .340). In regard to 186 
main effect of treatment condition, the results using this analysis were identical to those 187 
presented above for total time. For the main effect for time per kilometre, post-hoc analysis 188 
indicated that the final kilometre was run significantly faster than kilometres 1 -4 (all P = 189 
0.08 or better, See Figure 2). Mean ± SE data of time per kilometre across the different 190 
treatment conditions does appear to show different pacing strategies in Figure 2, particularly 191 
for the placebo condition. However, there was no significant time per kilometre X treatment 192 
interaction (P = .324). 193 
 194 
In respect of heart rate (Table 2), there was no significant effect of treatment (P = .210) or 195 
treatment X time interaction (P = .730). There was a large significant main effect for time (P 196 
= .0001, Pɳ2 = .703).These findings were mirrored for BLa (Table 2) with no significant 197 
effect of treatment (P = .132) or treatment X time interaction (P = .721) but a large significant 198 
main effect for time (P = .0001, Pɳ2 = .803) and also for RPE (Table 2) where again there 199 
was no significant effect of treatment (P =. 300) or treatment X time interaction (P = .566) 200 
but a large significant main effect for time (P = .0001, Pɳ2 = .927). In each case, HR, BLa 201 
and RPE significantly increased with each successive Km ran, irrespective of substance 202 
ingested. These main effects are presented in Figure 3a, b and c. 203 
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 204 
***Table 2 Here*** 205 
 206 
 207 
When measures of affect were examined, results from a 4 (treatment) X 3 (time, Pre 208 
ingestion, post ingestion, post exercise) for scores on the Felt Arousal Scale indicated no 209 
significant main effect for treatment (P = .505) or time X treatment interaction (P = .335). 210 
There was however a large significant main effect for time (P = .009, Pɳ2 = .546, See Figure 211 
4) whereby felt arousal increased pre ingestion to post ingestion (P = .028) with the 212 
difference also being significantly different from pre ingestion to post exercise (P = .026) but 213 
with no difference between post ingestion and post exercise (P = .084). Mean ± SE and 95% 214 
Confidence Intervals for felt arousal scores and Feeling scales scores pre ingestion, post 215 
ingestion and pre exercise and post exercise across placebo, R.Rosea, caffeine and combined 216 
caffeine and R.Rosea trials is presented in Table 3. 217 
 218 
***Table 3 Here*** 219 
 220 
When scores from the Feeling Scale were examined there was a small significant treatment X 221 
time interaction (P = .011, Pɳ2 =.255, See Figure 5). Post-Hoc analysis indicated no 222 
significant differences in feeling scale scores pre ingestion (P = .693) or post ingestion (P 223 
=.431). However, Post exercise feeling scale scores in the caffeine condition were 224 
significantly lower as compared to the Caffeine + R.Rosea condition (P = .027) and the 225 
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R.Rosea condition (P = .05). There were also no significant differences pre ingestion to post 226 
ingestion and post exercise for Placebo, R.Rosea and Caffeine + R.Rosea conditions (all P 227 
>.05). For the caffeine condition there was significantly lower feeling scales scores post 228 
exercise compared to pre ingestion (P = .019) and post ingestion (p = .001). 229 
 230 
Discussion 231 
The present study is the first to combine caffeine and R.Rosea when examining exercise 232 
performance. This is despite there being plausible evidence that both substances are 233 
ergogenic alone and that potentially, when combined might be synergistic, due to caffeine 234 
acting directly on muscle
25
 and the CNS
1
 and suggestions that R.Rosea results in increased 235 
endogenous opioid production.
17
 236 
The results of the present study suggest that ingestion of 3 mg·kg
-1
caffeine has a 237 
significant and positive effect on 5km run time in recreationally active males. The ingestion 238 
of R.Rosea or R.Rosea combined with caffeine did not significantly improve 5km running 239 
performance. When compared against performance in the placebo condition, 5km time trial 240 
time following caffeine ingestion was approximately 5% faster than the placebo trial. Such a 241 
magnitude of change in the presence of caffeine is greater than that reported by O’Rourke et 242 
al
3
 following ingestion of a larger bolus of caffeine (5mg·kg
-1
) for 5km run and by Bridge 243 
and Jones
4
 following ingestion of 3 mg·kg
-1
caffeine for 8km run. Likewise, although not 244 
significant, there was a 3.5% improvement following R.Rosea ingestion and a 4% 245 
improvement following combined R.Rosea and Caffeine ingestion when compared against 246 
the placebo condition.  The reason for the larger performance improvement seen in the 247 
caffeine trial may be attributed to a number of reasons. The participants utilised by O’Rourke 248 
et al
3
 were a mixture of trained and non-trained runners and those used by Bridge and Jones
4
 249 
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were trained runners. Prior systematic review data suggested lack of standardisation of 250 
training status may be one reason for the equivocal nature of the effects of caffeine on 251 
exercise performance and that the effect of caffeine on performance may differ in individuals 252 
of different training status.
26
 In the present study, recreationally active men who were not 253 
specifically running trained, nor were they competitive runners. Secondly, in both the 254 
aforementioned studies, experimental trials took place outdoors, providing ample opportunity 255 
for pacing by participants. The present study utilised a different methodology whereby 256 
participants ran on a treadmill and had access to buttons to increase or decrease running 257 
speed. There were no other available metrics to the participants, thus removing any explicit 258 
cues for pacing. This lack of feedback may have resulted in lesser likelihood of a belief effect 259 
interacting with the time trial task employed in the current study. 260 
 Taken collectively, these results would appear to support the ingestion of caffeine 261 
alone as a means to enhance 5km time trial running performance. This finding adds further 262 
support for the use of caffeine as a performance enhancer in short-term endurance activity.
3,4
 263 
The current results also question the validity of claims regarding the efficacy of acute 264 
R.Rosea ingestion as a means to enhance exercise performance.
18
 Similarly, R.Rosea or 265 
combined caffeine and R.Rosea ingestion did not significantly influence the affect either after 266 
ingestion or after exercise. This is also contrary to prior research by Duncan and Clarke
11
 267 
using steady state exercise that suggested R.Rosea positively enhanced affect. The 268 
discrepancy in findings regarding R.Rosea ingestion in the present study compared to prior 269 
work
17,18 
may be due to a number of reasons relating to the methodologies employed in prior 270 
work and the current study. In the study by DeBock et al
17
 a time to exhaustion test was used. 271 
Authors have questioned the validity of this methodology because it does not mimic the 272 
demands of most athletic events which require individuals to cover a set distance in the 273 
quickest time possible.
27
 Although this point was addressed in the subsequent study by 274 
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Noreen et al
18
, their design made feedback data available to participants during the time trial 275 
task they used. This procedure is also problematic when examining the potential effects of 276 
ingesting substances as athletes may pace using the available feedback and substance 277 
ingestion can also elicit belief effects,
28
 which can be both positive and negative
29
. In the 278 
present study, the use of a time-trial task without feedback would have limited any potential 279 
interaction of potential belief effects with time trial pacing, resulting in a more accurate 280 
demonstration of the effects of the various substances ingested. Of interest, in the present 281 
study, acute caffeine ingestion resulted in significantly greater negative affect (feeling states) 282 
post exercise compared to the other trials. Few studies have examined how affect changes as 283 
a consequence of substance ingestion and exercise making it difficult to explain the findings 284 
presented here. The results presented here are contrary to work by Astorino et al
30
 which 285 
reported improved scores for feeling states during a 10km cycling time trial in the presence of 286 
caffeine compared to placebo. Athletes may therefore performance benefit from ingestion of 287 
caffeine, but not R.Rosea, for short term endurance running performance. The present study 288 
also illustrates the importance of investigating the combination of two potentially ergogenic 289 
substances on performance. Theoretically, there appears to be a basis for a synergistic effect 290 
of combining caffeine and R.Rosea. In practice, when these substances were combined, there 291 
appeared to be no advantage to ingestion of caffeine and R.Rosea over ingestion of a placebo. 292 
The reason for this is not known and it may be that when combined, additional side effects 293 
are realised (although none of these were reported by participants) which do not occur when 294 
either caffeine or R.Rosea are combined in isolation. Additional research would be needed to 295 
examine this point specifically. 296 
The current study does have some limitations. We recruited participants who were 297 
recreationally active but were not trained athletes. It has been suggested that less fit 298 
individuals may experience greater fatigue and discomfort during exercise which may reduce 299 
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feelings of pleasure and compared to more highly trained individuals.
11
 It may therefore be 300 
useful to compare the responses of participants of different training status in order to make 301 
more conclusive statements regarding the effect of the substances, either alone or in 302 
combination on variables such as, perception of exertion, arousal and pleasure. The 303 
assessment of affect immediately on completion of the running bouts might have resulted in 304 
elevated scores for feeling states due to the cessation of exercise as has been suggested 305 
previously.
31
 It may be that the trajectory of pleasure and displeasure during and after 306 
exercise exhibits two distinct phases.
31
 The first phase involves a decline or increase of 307 
affective responses during exercise, whereas the second phase involves an improvement or 308 
rebound of affective responses after exercise. As measures of affect were only taken on 309 
completion of the exercise bouts, the data presented here are only representative of the 310 
rebound phase of exercise in the presence of caffeine, R.Rosea, combined caffeine and 311 
R.Rosea and placebo.  Future research should therefore, attempt to assess affect during 312 
exercise in addition to immediately on cessation in order to more effectively capture the time 313 
course of affective responses to exercise following ingestion of different substances.  314 
 315 
Conclusions  316 
The current study suggests that acute caffeine ingestion (3 mg·kg
-1
) enhances 5km time trial 317 
performance undertaken on a treadmill and also results in more negative affect post exercise 318 
as compared to ingestion of R.Rosea, combined R.Rosea and caffeine and placebo. As a 319 
consequence this study supports the efficacy of caffeine as an ergogenic aid but also suggests 320 
that acute ingestion of R.Rosea either alone or with caffeine does not enhance performance 321 
over a placebo. 322 
 323 
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 Figure 1. Mean ± SE of total 5km time across placebo, R.Rosea, caffeine and combined 
caffeine and R.Rosea trials 
 
Figure 2. Mean ± SE of time per kilometre across placebo, R.Rosea, caffeine and combined 
caffeine and R.Rosea trials 
 
Figure 3. Main effects (Mean ± SE) for  a) heart rate (BPM), b) Blood lactate (mmol/L) , c) 
RPE (6-20),  per kilometre irrespective of substance ingested.  
 
Figure 4. Main effect for Felt Arousal per kilometre (Mean ± SE) irrespective of substance 
ingested. 
 
Figure 5. Mean ± SE of Feeling Scale scores pre ingestion, post ingestion but pre exercise 
and post exercise across placebo, R.Rosea, caffeine and combined caffeine and R.Rosea trials 
 





